NEW YORK (GenomeWeb) – It can be tricky business to determine when and how a new diagnostic technology ought to be used in order to best impact patients and costs. In a current debate over diagnostic stewardship for BioFire Diagnostics' meningitis and encephalitis molecular panel, the company and some laboratorians support unrestricted use of the test, while other lab experts have suggested that restrictions are needed, at least until more studies can be done.